Last reviewed · How we verify
US License Enbrel
US License Enbrel is a Small molecule drug developed by mAbxience Research S.L.. It is currently in Phase 1 development. Also known as: (etanercept).
US License Enbrel is an interleukin-6 inhibitor, a type of drug that falls under the class of inhibitors. It is being studied in a clinical trial (NCT06392074) for its safety, absorption, and elimination in healthy volunteers.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | US License Enbrel |
|---|---|
| Also known as | (etanercept) |
| Sponsor | mAbxience Research S.L. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- US License Enbrel CI brief — competitive landscape report
- US License Enbrel updates RSS · CI watch RSS
- mAbxience Research S.L. portfolio CI
Frequently asked questions about US License Enbrel
What is US License Enbrel?
Who makes US License Enbrel?
Is US License Enbrel also known as anything else?
What development phase is US License Enbrel in?
Related
- Manufacturer: mAbxience Research S.L. — full pipeline
- Also known as: (etanercept)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing